Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial nerve palsies, according to early results from a Phase 2 clinical trial reported Tuesday.
While still preliminary, the benign neurotoxicity assessment for the therapy, called anito-cel, suggests it could be a safer option for patients with multiple myeloma compared to Carvytki, a currently approved CAR-T treatment from Johnson & Johnson and Legend Biotech.
Parkinsonian symptoms and cranial nerve palsies have been reported in approximately 10% of patients treated with Carvykti, according to published clinical trial results.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in